Press Release: Novartis receives approval for -2-

Novartis

95.41 CHF -0.82%

• Charts
• News
• Analysen

Kaufen Verkaufen

References

1. Eight African countries participated in Swissmedic's Marketing

Authorization for Global Health Products (MAGHP) procedure

https://www.swissmedic.ch/swissmedic/en/home/about-us/development-cooperation/marketing-authorisation-for-global-health-products.html

for Coartem Baby -- Burkina Faso, Cote d'Ivoire, Kenya, Malawi,

Mozambique, Nigeria, Tanzania and Uganda -- and are expected to approve

the medicine following approval by Swissmedic. These eight countries

account for 47% of estimated cases in 2023, according to the WHO's Global

Health Observatory

https://www.who.int/data/gho/data/indicators/indicator-details/GHO/estimated-number-of-malaria-deaths

2. WHO. Malaria vaccines (RTS,S and R21)

https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine#::text=Malaria%20vaccines%20should%20be%20provided%20to%20children%20in%20a%20schedule,

age%20based%20on%20operational%20considerations.

3. Reddy, Valentina et al. Global estimates of the number of pregnancies at

risk of malaria from 2007 to 2020: a demographic study. The Lancet Global

Health, Volume 11, Issue 1, e40 - e47

4. Ceesay SJ et al. Malaria Prevalence among Young Infants in Different

Transmission Settings, Africa. Emerg Infect Dis. 2015 Jul;21(7):1114-21.

doi: 10.3201/eid2107.142036. PMID: 26079062; PMCID: PMC4480393.

5. D'Alessandro U, et al. Malaria in infants aged less than six months - is

it an area of unmet medical need? Malar J. 2012 Dec 2;11:400. doi:

10.1186/1475-2875-11-400. PMID: 23198986; PMCID: PMC3529680.

6. Dobbs, et al. Plasmodium malaria and antimalarial antibodies in the first

year of life. Parasitology. 2016;143(2):129-138.

doi:10.1017/S0031182015001626

7. WHO. Malaria. https://www.who.int/news-room/fact-sheets/detail/malaria

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

July 08, 2025 01:15 ET (05:15 GMT)